1. Home
  2. PANW vs AMGN Comparison

PANW vs AMGN Comparison

Compare PANW & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Palo Alto Networks Inc.

PANW

Palo Alto Networks Inc.

N/A

Current Price

$347.03

Market Cap

287.9B

Sector

Technology

ML Signal

N/A

Logo Amgen Inc.

AMGN

Amgen Inc.

N/A

Current Price

$437.81

Market Cap

251.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PANW
AMGN
Founded
2005
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
287.9B
251.6B
IPO Year
2012
2002

Fundamental Metrics

Financial Performance
Metric
PANW
AMGN
Price
$347.03
$437.81
Analyst Decision
Buy
Hold
Analyst Count
55
34
Target Price
$409.23
★ $435.77
AVG Volume (30 Days)
★ 6.2M
2.1M
Earning Date
11-18-2026
11-03-2026
Dividend Yield
N/A
★ 2.30%
EPS Growth
N/A
★ 88.23
EPS
0.57
★ 14.79
Revenue
$2,273,100,000.00
★ $25,424,000,000.00
Revenue This Year
$26.84
$7.45
Revenue Next Year
$14.73
$4.54
P/E Ratio
$634.61
★ $29.67
Revenue Growth
★ 29.04
8.83
52 Week Low
$139.57
$312.39
52 Week High
$432.33
$483.99

Technical Indicators

Market Signals
Indicator
PANW
AMGN
Relative Strength Index (RSI) 49.33 41.75
Support Level $314.25 $338.02
Resistance Level $374.77 $446.42
Average True Range (ATR) 17.97 11.75
MACD 2.69 -4.96
Stochastic Oscillator 64.21 4.16

Price Performance

Historical Comparison
PANW
AMGN

About PANW Palo Alto Networks Inc.

Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Share on Social Networks: